Evidence map›Paper›PMID 37609279›Full record

ArticleResearch square2023

Identification of Selective ATP-Competitive CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function.

Shengyan Xiang, Xingju Luo, Darcy Welch, Damon R Reed, Mark G Alexandrow

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shengyan XiangCancer Biology and Evolution Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612.
Xingju LuoCancer Biology and Evolution Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612.
Darcy WelchCancer Biology and Evolution Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612.
Damon R ReedCancer Biology and Evolution Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612.
Mark G AlexandrowCancer Biology and Evolution Program, Moffitt Cancer Center and Research Institute, Tampa, FL 33612.ORCID 0000-0003-4661-0368
Moffitt Cancer Center · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Direct Control of the human CMG Helicase by Myc and RbR01GM140140 · NIGMS · H. LEE MOFFITT CANCER CTR & RES INST · PI ALEXANDROW, MARK G. · 2021 to 2024
$1.3M
MCM Helicase as a Novel Target for Pancreatic Cancer TreatmentR21CA155393 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ALEXANDROW, MARK G. · 2011 to 2012
$400k
NCI NIH HHS P30 CA076292NCI NIH HHS R21 CA155393NIGMS NIH HHS R01 GM140140
6 · The paper itself

Abstract

The human CMG helicase (Cdc45-MCM-GINS) is a novel target for anti-cancer therapy due to tumor-specific weaknesses in CMG function induced by oncogenic changes and the need for CMG function during recovery from replicative stresses such as chemotherapy. Here, we developed an orthogonal biochemical screening approach and identified selective CMG inhibitors (CMGi) that inhibit ATPase and helicase activities in an ATP-competitive manner at low micromolar concentrations. Structure-activity information and

Indexed as

aminocoumarinCdc45CMG helicaseDNA replicationGINSMCM

Identifiers

PMID37609279
PMCPMC10441460
OpenAlexW4385766178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.